Wird geladen …
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
BACKGROUND: Chimeric antigen receptor - T (CAR-T) cell therapy has shown remarkable efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). However, a subset of patients still experienced progression or relapse, and the predictors of prognosis are little known. We analyzed the infla...
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Online Artikel Text |
Sprache: | English |
Veröffentlicht: |
Frontiers Media S.A.
2023
|
Schlagworte: | |
Online Zugang: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154462/ https://www.ncbi.nlm.nih.gov/pubmed/37153543 http://dx.doi.org/10.3389/fimmu.2023.1169071 |